Main page | Veltassa

Veltassa^®

Providing sustained, around the clock control of your patients’ K⁺, and proven to allow guideline-recommended RAASi therapy. Veltassa^® is reliable and easy to use with no sodium-associated risk.^1–7

On this page

WHAT IS VELTASSA®

MOA

ONCE DAILY

SAFETY & TOLERABILITY

NO SODIUM RISK

VELTASSA^®

What is Veltassa^®?

Veltassa^® (patiromer sorbitex calcium) is a novel, next-generation, non-absorbed cation exchange polymer indicated for the treatment of hyperkalemia in adults.^6,7

Veltassa^® has been designed specifically to exchange K⁺ for Ca²⁺ rather than Na⁺.⁷

Veltassa^® increases faecal K⁺ excretion by exchanging Ca²⁺ for K⁺ in the lumen of the GI tract and reducing serum levels of this cation^7,8

Ca² ions released during the ion-exchange process may be absorbed, rebind to Veltassa®, remain in solution, or bind to anions, such as phosphate, to form relatively insoluble salt complexes

Veltassa^® has been designed to be fully ionised at the physiological pH of the colon, where the concentration of K⁺ in the GI tract is highest,^6,9 for optimal ion exchange

Veltassa^® has a 1.5–2-fold higher K⁺ binding capacity than other polymers⁶

Veltassa^® is not absorbed and remains physically intact during its passage through the GI tract⁷

VELTASSA^®

Veltassa® Mode of Action

Veltassa^® is manufactured using a suspension polymerisation process that results in insoluble spherical beads of uniform and controlled size.

Veltassa^®’s smooth microbead structure and low swelling ratio may minimise undesirable GI effects and lead to improved tolerability for patients.⁶

VELTASSA^®

Veltassa^® is the once daily solution for long-term K⁺ control

1 MIX

Mix 3 tablespoons of water or alternative liquid/soft food with an entire sachet of Veltassa^®, then stir⁷

2 ADD

Add another 3 tablespoons of water or alternative liquid/soft food and stir thoroughly. The powder will not dissolve and the mixture will look cloudy⁷

3 DRINK

Drink immediately. If powder remains in the glass after consuming, repeat steps 2 and 3 to ensure the entire dose is taken⁷

Simple and easy

Simple and easy once-daily dosing from the start^7,10

Veltassa® can be suspended in apple or cranberry juice for added flavour⁷
Veltassa® can be mixed with a range of liquids and soft foods for added flavour⁷*
In a palatability study of 62 subjects, ≥90% of patients found Veltassa® to be a positive experience in terms of odour or taste¹¹

Flexibility

Flexibility with juice options, soft foods and other liquids to suit individual tastes^7,11

The majority of the ADRs reported from trials were gastrointestinal disorders and hypomagnesaemia⁷
GI ADRs were generally mild-to-moderate in nature and did not appear to be dose-related. They generally resolved spontaneously or with treatment, and none were reported as serious⁷
No patients developed magnesium levels <1 mg/dL.⁷ Serum magnesium should be monitored for at least 1 month after initiating treatment, and magnesium supplementation considered in patients who develop low serum magnesium levels

VELTASSA^®

Favourable safety & tolerability

Veltassa^® has demonstrated a positive risk/benefit profile in hyperkalemia management from both the clinical trial programme and real-world practice.

ADRs in clinical studies
System Organ Class	Common	Uncommon
Metabolism and nutrition disorders	Hypomagnesemia:5.3%
Gastrointestinal disorders	Constipation:6.2% Diarrhoea:3% Abdominal pain:2.9% Flatulence:1.8%	NauseaVomiting

No dose-related oedema observed in over 52 weeks of treatment²
Hypokalemia was not identified as an ADR²

The majority of the ADRs reported from trials were gastrointestinal disorders and hypomagnesemia⁷

GI ADRs were generally mild-to-moderate in nature and did not appear to be dose-related. They generally resolved spontaneously or with treatment, and none were reported as serious⁷

No patients developed magnesium levels <1 mg/dL.⁷ Serum magnesium should be monitored for at least 1 month after initiating treatment, and magnesium supplementation considered in patients who develop low serum magnesium levels⁷

The favourable safety profile observed in clinical trials is supported by evidence from real-world studies.

In real-world practice, an estimated >400,000 patients have been exposed to Veltassa®.¹²

VELTASSA^®

No sodium risk

Excess Na⁺ intake is associated with increased CV and renal risks:^2–12

Increased blood pressure^13-15

Decreased reno-protective benefits of RAASi medication^16-18

CV morbidity and mortality^13,19-22

Increased albuminuria^15,23

Veltassa^® is suitable for sodium-sensitive patients

The use of Ca²⁺ rather than Na⁺ may make Veltassa^® a good choice for hyperkalemia management in patients who cannot tolerate even small increases in Na⁺, such as patients with HF, CKD, severe hypertension or marked oedema⁶

DOWNLOAD VELTASSA® SUMMARY